DNA修复基因在基于铂类药物化疗的非小细胞肺鳞癌患者中的预后价值  

Prognostic value of DNA repair genes in non-small cell lung squamous carcinoma patients received platinum-based chemotherapy

作　　者：谢科杰[1] 何红尔[1] 王兴木[1] 王美丹[1] 吴东东[1] Xie Kejie;He Honger;Wang Xingmu;Wang Meidan;Wu Dongdong(Shaoxing People’s Hospital,Shaoxing Hospital of Zhejiang University,Shaoxing Zhejiang 312000,China)

机构地区：[1]绍兴市人民医院浙江大学绍兴医院,浙江绍兴312000

出　　处：《中华临床实验室管理电子杂志》2020年第1期6-12,共7页Chinese Journal of Clinical Laboratory Management(Electronic Edition）

基　　金：绍兴市科技计划项目(2015B70043)。

摘　　要：目的了解DNA修复基因在接受以铂类药物为基础化疗的非小细胞肺癌(NSCLC患者中不同病理类型的预后价值。方法应用免疫组织化学技术检测121例NSCLC铂类药物化疗患者石蜡包埋病灶组织中多聚ADP-核糖聚合酶基因1(PARP1),切除修复交叉互补基因1(ERCC1),错配修复同源型2基因(MSH2),乳腺癌易感基因1(BRCA1)表达状态。分析NSCLC患者DNA修复基因的表达与临床病理特征之间的关系。并通过生存分析判断DNA修复基因的表达在不同病理类型中NSCLC化疗患者中的预后价值及是否为独立的预后指标。结果 ERCC1、PARP1、BRCA1、MSH2在非小细胞肺癌的表达均未显示与患者的性别、年龄、吸烟指数、临床TNM分期的相关性(P均> 0.05)。在NSCLC腺癌组中ERCC1、PARP1、BRCA1、MSH2均不是判断预后的独立因素(P均> 0.05)。鳞癌组中ERCC1、PARP1是预后判断独立因素(P=0.019,0.031)。结论 ERCC1、PARP1是基于铂类药物化疗的非小细胞肺鳞癌患者独立的预后指标。Objective To explore the prognostic value of DNA repair genes in patients with different pathological types of non-small cell lung cancer(NSCLC)and were all received platinum-based chemotherapy.Methods Immunohistochemical technique was used to measure the expression levels of the following DNA repair genes:poly ADP-ribose polymerase gene 1(PARP1),excision and repair of cross-complementing gene 1(ERCC1),mismatch repair and homology type 2 gene(MSH2),breast cancer susceptibility gene 1(BRCA1)in paraffin embedded lesions of 121 NSCLC patients received platinum-based chemotherapy.The relationship between the expression levels of DNA repair genes and clinicopathological features in NSCLC patients was analyzed.The prognostic value of DNA repair gene expression level in NSCLC patients with different pathological types and whether it is an independent prognostic index were determined by survival analysis.Results The expression of ERCC1,PARP1,BRCA1 and MSH2 in NSCLC was not correlated with gender,age,smoking index and clinical TNM staging(P>0.05).ERCC1,RARP1,BRCA1,and MSH2 were not independent prognostic factors in NSCLS adenocarcinoma patients(P>0.05).But ERCC1 and PARP1 were independent prognostic factors in NSCLS squamous patients(P=0.019,0.031).Conclusion ERCC1 and PARP1 are independent prognostic markers of NSCLC SCC patients received platinum-based chemotherapy.

关 键 词：DNA修复基因 非小细胞肺癌 化疗 鳞癌 预后 

分 类 号：R734.2[医药卫生—肿瘤]